177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1 - Strosberg, JR; Caplin, ME; Kunz, PL (Lancet Oncol, 2021)
et al.